Atomoxetine

Pediatric Drugs

Volumn 5, Issue 6, 2003, Pages 407-415

  Simpson, Dene ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; FLUOXETINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; QUINIDINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; ASTHENIA; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; BODY WEIGHT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; EUPHORIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IN VITRO STUDY; INSOMNIA; LONG QT SYNDROME; NAUSEA; NORADRENALIN UPTAKE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RHINITIS; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; VERTIGO; VOMITING; WEIGHT REDUCTION;

EID: 0037862033     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200305060-00005     Document Type: Review

References (39)

1. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996 Apr; 35: 409-32
2. Biederman J, Spencer T. Non-stimulant treatments for ADHD. Eur Child Adolesc Psychiatry 2000; 9 Suppl. 1: 151-9
3. Cyr M. Brown CS. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs 1998 Aug; 56: 215-23
4. Zametkin AJ, Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. N Engl J Med 1999 Jan 7; 340: 40-6
5. Swanson JM, Sergeant JA, Taylor E, et al. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 1998 Feb 7; 351: 429-33
6. Wilens TE, Biederman J. Spencer TJ. Pharmacotherapy of attention deficit hyperactivity disorder in adults. CNS Drugs 1998; 9 (5): 347-56
7. Spencer TJ, Biederman J, Wilens T, et al. Overview and neurobiology of attention/hyperactivity disorder. J Clin Psychiatry 2002; 63 Suppl. 12: 3-9
8. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63 (12): 1140-7
9. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999 Mar 11; 340: 780-8
10. Biederman J, Spencer TJ, Lombroso P. Genetics of childhood disorders: XIX. ADHD (Pt 3): is ADHD a noradrenergic disorder? J Am Acad Child Adolesc Psychiatry 2000; 39 (10): 1330-3
11. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 1999 May; 38: 503-12
12. Safer DJ. Central stimulant treatment of childhood attention deficit hyperactivity disorder: issues and recommendations from a US perspective. CNS Drugs 1997 Apr; 7: 264-72
13. Pliszka SR. The use of psychostimulants in the pediatric patient. Pediatr Clin North Am 1998 Oct; 45: 1085-98
14. Wong DT, Threlkeld PG, Best KL, et al. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 1982; 222 (1): 61-5
15. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999; 46 (9): 1234-42
16. Iversen L. Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry 2000; 5: 357-62
17. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52 (12): 1023-9
18. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002 Nov; 27 (5): 699-711
19. Zerbe RL, Rowe H, Enas GG, et al. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther 1985 Jan; 232 (1): 139-43
20. 3H] tomoxetine, an enantiomerically pure ligand for epinephrine reuptake sites. Neurosci Lett 1993 Jul 23; 157 (2): 203-6
21. 3H]nisoxetine binding in rat brain. J Neurochem 1995 Jun; 64 (6): 2792-800
22. Stahl SM. Neurotransmission of cognition (Pt 2). Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry 2003 Feb; 64 (2): 110-1
23. Fuller RW, Hemrick-Luecke SK. Antagonism by tomoxetine of the depletion of norepinephrine and epinephrine in rat brain by α-methyl-m-tyrosine. Res Commun Chem Pathol Pharmacol 1983 Jul; 41 (1): 169-72
24. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994 May; 114 (4): 559-65
25. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002 Nov; 159 (11): 1896-901
26. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108 (5): E83-91
27. Wernicke JF, Faries D, Kovacs R, et al. Cardiovascular effects of atomoxetine in children and adolescents [abstract no. A21]. 49th Annual Meeting of the American Academy of Child and Adolescent Pyschiatry; 2002 Oct 22-27; San Fransisco, 92
28. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63 Suppl. 12: 50-5
29. Wernicke JF, Schuh KJ, Zhang S, et al. Safety of atomoxetine in children and adolescents treated for at least 1 year for attention-deficit/hyperactivity disorder [abstract no. P.3.W.018 and poster]. Collegium Internationale NeuroPsychopharmcologium (CINP); 2002 Jun 23-27; Montreal, S163
30. Belle DJ, Ernest CS, Sauer J-M, et al. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002 Nov; 42 (11): 1219-27
31. Witcher JW, Kurtz DL, Sauer J-M, et al. Pharmacokinetic/dynamic relationship of atomoxetine exposure and efficacy [abstract no. NR450]. American Psychiatric Association 2002 Annual Meeting; 2002 May 18-23; Philadelphia, 121-2
32. Desager J, Desager J-P, Chalon S, et al. Pharmacokinetics (PK) of atomoxetine (ATM) in hepatically impaired (HI) patients [abstract no. WPIII-85]. 2002 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2002 Mar 24-27; Atlanta, P99
33. Eli Lilly. Strattera R (atomoxetine HC1) [online]. Available from URL: www.lilly.com [Accessed 2003 Feb 10]
34. Kratochvil CJ, Bohac D, Harrington M, et al. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001 Summer; 11 (2): 167-70
35. Spencer T, Biederman J, Heiligenstein J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001 Fall; 11 (3): 251-65
36. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002 Jul; 41 (7): 776-84
37. Biederman J, Heiligenstein JH, Faries DE, et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics 2002 Dec; 110 (6): E75-81
38. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002 Jul 1; 67 (2): 149-56
39. Chalon SA, Desager J-P, DeSante KA, et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 2003 Mar; 73 (3): 178-91